Equities researchers at StockNews.com started coverage on shares of InspireMD (NYSE:NSPR - Get Free Report) in a research report issued on Sunday. The firm set a "sell" rating on the stock.
Separately, Piper Sandler restated an "overweight" rating and issued a $4.50 target price on shares of InspireMD in a research note on Tuesday, September 17th.
Get Our Latest Stock Report on NSPR
InspireMD Stock Performance
Shares of NYSE:NSPR traded down $0.10 during mid-day trading on Friday, hitting $2.28. 16,440 shares of the company traded hands, compared to its average volume of 26,272. The firm's 50 day simple moving average is $2.60 and its 200 day simple moving average is $2.58. The firm has a market cap of $56.84 million, a P/E ratio of -3.08 and a beta of 0.93. InspireMD has a 52-week low of $1.81 and a 52-week high of $3.42.
Institutional Trading of InspireMD
An institutional investor recently bought a new position in InspireMD stock. Affiance Financial LLC bought a new position in InspireMD, Inc. (NYSE:NSPR - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 183,746 shares of the company's stock, valued at approximately $492,000. Affiance Financial LLC owned approximately 0.74% of InspireMD at the end of the most recent quarter. Institutional investors and hedge funds own 44.78% of the company's stock.
About InspireMD
(
Get Free Report)
InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.
Featured Articles
Before you consider InspireMD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InspireMD wasn't on the list.
While InspireMD currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
